Physician profile
Robert Anderson
NPI 1861514929
$13,598.49
in general payments reported to CMS, 2019-2025
42 companies · $2,065 in 2025
The $2,065 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $1,151 · 2021: $1,615 · 2022: $2,325 · 2023: $2,755 · 2024: $2,402 · 2025: $2,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,961 · Education: $246 · Travel and Lodging: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,961.37 |
| Education | $246.46 |
| Travel and Lodging | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,298.88 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,251.53 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,125.27 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $1,009.39 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $733.08 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $606.18 | 2019-2025 | Resolution 360 Clip, Exalt Model D, Enhance Transcarotid Peripheral Access Kit |
| Qol Medical, LLC | $377.13 | 2019-2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $323.12 | 2019-2025 | Rebyota, Clenpiq |
| Merck Sharp & Dohme LLC | $322.65 | 2022-2024 | Dificid, Zerbaxa, Recarbrio |
| Allergan, INC. | $297.28 | 2019-2020 | |
| Pfizer INC. | $291.34 | 2021-2025 | |
| Genzyme Corporation | $225.60 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $189.17 | 2021-2023 | |
| Fujifilm Healthcare Americas Corporation | $186.84 | 2024 | Fujifilm |
| Regeneron Healthcare Solutions, INC. | $150.36 | 2022-2024 | Dupixent |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$34,238.94 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.